AUS
NZ
UK
CA
USA
IND
Highlights:
Imugene Ltd to host a live corporate webinar on April 16
Presentation will cover company updates and pre-submitted shareholder questions
Executive team including CEO and COO will lead the discussion
Imugene Ltd (ASX:IMU, OTC:IUGNF), a biotechnology company involved in the development of immunotherapies for cancer treatment, will conduct a live corporate webinar. The event is scheduled for mid-April and is designed to provide a comprehensive update on ongoing activities and strategic directions within the company.
This session aims to strengthen communication with shareholders and relevant stakeholders within the Healthcare stocks segment on the ASX 200, offering detailed responses to submitted questions.
Webinar Format and Leadership Participation
The webinar will be led by executive chairman Paul Hopper and will feature CEO and managing director Leslie Chong along with chief operating officer Bradley Glover. The presentation will serve to deliver detailed updates on the company's research, operational milestones, and corporate strategies.
A live Q&A component will be included, focusing on frequently asked shareholder questions. These questions can be submitted via the designated company email address in advance of the webinar. This allows for structured preparation and addresses key topics of interest among participants.
Access and Availability of Event Material
Participation in the webinar requires prior registration through an online platform. After registration, attendees will be granted access to the live stream on the specified date and time. Following the conclusion of the event, a recorded version will be made available through the same registration link.
Additionally, the recorded session will be published on Imugene Ltd’s official digital channels, ensuring broader accessibility for those unable to attend in real time. This aligns with the company's intent to maintain transparency and provide timely updates on its development pipeline and operational framework.
Stakeholder Communication Strategy
The initiative supports Imugene’s ongoing efforts to enhance its stakeholder communication strategy within the biotechnology sector. The webinar format enables direct engagement while providing verified updates from company leadership.
By involving key members of its executive team, the company reaffirms its commitment to information sharing across all operational levels. This practice is aligned with the broader communication standards expected from listed entities within the ASX 200, especially among Healthcare stocks navigating advanced clinical and preclinical development pathways.
Further Details and Digital Accessibility
Imugene Ltd encourages all interested stakeholders to register promptly to secure access to the live session. The option to submit questions in advance allows for more tailored responses and structured content delivery during the event.
The availability of the recorded session shortly after the live broadcast ensures continued access to the information presented, supporting Imugene’s broader mission to maintain transparency across its ongoing projects and developments.
